“Taking into account public health needs and given sufficient mRNA Covid-19 vaccines supply can be expected going forward, we have decided not to pursue the development of our Covid-19 mRNA candidate into a Phase 3 clinical study,” the company said in a statement.
“We will focus our mRNA resources in our newly created mRNA Center of Excellence to address future pandemics and other infectious diseases and therapeutics where there is a strong unmet need,” it added.
For the new study, Sanofi on September 14 acquired Translate Bio — a clinical-stage biotechnology company that specialises in mRNA therapies. The two teams had worked closely together since 2018 to design and develop a messenger RNA (mRNA) technology platform for vaccines.
The platform is the basis for an array of innovations to fight multiple pathogens. The newly combined R&D teams are now focused on the launch of our mRNA Center of Excellence which aims to unlock the potential of next-generation mRNA vaccines and other strategic areas such as immunology, oncology, and rare diseases, the company said.
In December, last year, the Sanofi-GSK faced a major setback after their experimental Covid-19 vaccine did not appear to work well in older adults.
Source: IANS
